Arizona is bucking a hopeful national trend, and the numbers demand attention from anyone touched by the opioid crisis in the Southwest. In part, The Grand Canyon State features a wide range of comprehensive treatment options, from residential care to local Narcotics Anonymous chapters. But even as naloxone use is saving more lives, overdose death rates continue to outpace recovery efforts.

While overdose deaths dropped roughly 15% nationally in 2025, Arizona’s opioid overdose deaths surged by more than 17%, according to the Centers for Disease Control and Prevention. For families, people in recovery, and harm reduction workers on the ground in Arizona, the statistics reflect a painful reality. Fentanyl and polysubstance drug use are overwhelming communities faster than progress can take hold.

The Opioid Crisis by the Numbers in Arizona

Arizona’s overdose reversals in which naloxone restores breathing after an opioid overdose nearly tripled in 2025. That rise in life-saving interventions signals both a worsening crisis and a growing harm reduction infrastructure fighting back against it. 

Dr. Martín Celaya, chief of the Bureau of Assessment and Evaluation at the Arizona Department of Health Services, reported that 90% of overdose deaths in the state involve polysubstance use, meaning more than one kind of drug was involved.

The most common combination driving fatal opioid overdoses is methamphetamine and fentanyl, Celaya noted. Critically, many victims may not have known what they were consuming. Celaya explained that some individuals simply didn’t know their methamphetamine was laced with fentanyl, or vice versa.

Drivers of Opioid Overdose Deaths in Arizona

Law enforcement partners have told the Arizona Department of Health Services that Arizona functions as a distribution hub for illicit drugs, including deadly additives and new compounds that can make drugs significantly more potent.

The opioid overdose death rate in Arizona is also being fueled by illicitly manufactured fentanyl, the synthetic opioid that is now the leading driver of drug fatalities nationwide. Fentanyl is 50x more potent than heroin and can be lethal in quantities invisible to the naked eye. Accidental overdoses are a constant risk, even for experienced drug users.

Fentanyl is increasingly found not only in the opioid supply but mixed into stimulants like methamphetamine and counterfeit pills. This pattern is proving especially deadly in Arizona’s drug market.

Naloxone Saves Lives but Gaps Remain

Despite the grim overdose statistics, one number in Arizona offers genuine hope. Sonoran Prevention Works (SPW), the largest harm reduction organization in Arizona, saw overdose reversals climb from roughly 2,500 in 2024 to more than 4,000 in 2025. Including community partners resourced through SPW, that reversal number reached nearly 6,000.

SPW CEO Scott Greenwood described his organization as the single largest non-government distributor of naloxone in the country.

Most people know naloxone through Narcan, its over-the-counter nasal spray form. Narcan can be expensive, but Greenwood noted that SPW has found success using the injectable intramuscular form, which carries a significant cost advantage and allows the organization to distribute far more doses across the state.

Naloxone rapidly blocks opioid receptors and reversing the respiratory depression that causes overdose death. It’s safe, effective, and can be administered by anyone — no medical training required.

Fentanyl Test Strips & Medication-Assisted Treatment

Greenwood also advocated strongly for expanded access to fentanyl test strips, which allow people to check their drugs for dangerous additives before use.

SPW is also exploring a direct clinical program for medication-assisted treatment (MAT) — a significant expansion for an organization that has historically focused on harm reduction referrals rather than direct treatment provision.

MAT includes medications like buprenorphine (Suboxone) and methadone to combat withdrawals. Combined with counseling and peer support through programs like Narcotics Anonymous, MAT dramatically reduces overdose risk and supports long-term recovery.

Help for Opioid Addiction in Arizona

If you or someone you love has an opioid or narcotic addiction in Arizona or elsewhere in the nation, recovery resources are available now.

NA holds meetings across Arizona. NA meetings are free, peer-led, and open to anyone struggling with narcotic addiction or opioid abuse. You can call 800-934-1582(Sponsored) to speak with an expert or browse our directory for meetings anywhere in the country.

When Hurricane Helene ripped through the mountains of western North Carolina and the greater Appalachia region in September 2024, it dismantled the Narcotics Anonymous meetings, opioid treatment programs, and peer support networks that thousands of people in recovery depended on to stay alive. 

North Carolinians are known for their resilience. The Tar Heel State features local NA chapters in virtually every neighborhood. Nevertheless, for communities already deep in the opioid crisis, losing those systems even temporarily meant a perilous climb back from the edge.

The Opioid Crisis by the Numbers

Appalachia was already fighting a losing battle against opioid addiction before the first floodwaters rose. Overdose mortality in Appalachian counties — spanning 13 states from New York to Mississippi — still exceeded the national average by 52% in 2023, driven by limited healthcare access, physically demanding work, and economic hardship. In six North Carolina counties alone, overdose deaths topped 36 per 100,000 residents in 2022.

Then Helene hit, and the numbers got worse in ways that won’t fully show up in data for years. Penn State sociologist Kristina Brant, who studies the long-term impacts of flooding, found an increase in overdose deaths that persists for a full decade after a major flood event. Grief and trauma, she notes, are significant triggers that can derail recovery. Indeed, hospitalizations for drug abuse jumped 30% after Hurricane Katrina and continued ascending for years, especially among the hardest-hit neighborhoods.

What’s Driving the Relapse Risk After Disasters

The backbone of opioid recovery isn’t just medication. Rather, it’s routine, community, and structure. Rural Appalachian communities lack the redundancies that make it easier to find another meeting, another clinic, or another therapist. Long travel distances are another hurdle, even during normal times.

When disasters like Helene hit and infrastructure is severely impacted, those existing barriers are “amplified a billion-fold,” according to Erin Major, a doctoral candidate in health services research at Boston University who studies substance misuse in Appalachia. These barriers make it genuinely impossible for many patients to access their care.

Devon, a 41-year-old Iraq war veteran in Asheville who asked to be identified only by his first name as required by 12-step program traditions, lived this firsthand. After returning from the Middle East with PTSD and a traumatic brain injury, he struggled with opioid addiction — beginning with prescription pills, then heroin — before finding stability through Narcotics Anonymous, medication-assisted treatment, and therapy. 

Helene didn’t just damage his house. It fractured Devon’s marriage, upended his NA meeting schedule, halted therapy, buried him in financial strain, and eventually left him feeling suicidal.

“I was in a war situation,” he said of the night of the storm. What came after was its own kind of combat.

Fentanyl’s Role and the Danger of Post-Disaster Relapse

The opioid crisis has been reshaped by fentanyl, and that matters acutely when people in recovery relapse after disasters. After even a brief period of sobriety, opioid tolerance begins to drop — making the immediate days of relapse among the most dangerous due to a significantly elevated risk of overdose. Street supplies increasingly contaminated with fentanyl make that window of risk even more lethal.

John Kennedy, a musician and harm reduction advocate in Buncombe County, had spent years distributing naloxone — the opioid overdose reversal medication — to local music venues and nightclubs. After Helene, venue after venue closed permanently, leaving fewer spaces to put naloxone in the hands of folks who use drugs. Kennedy worries that more people are now using opioids alone, in which naloxone can’t save a life because no one else is there to administer it.

Narcotics Anonymous and Peer Recovery When the System Breaks Down

Despite everything, Devon didn’t relapse. He credits Narcotics Anonymous with making the difference.

“This is, like, why we do what we do — when shit hits the fan,” he noted.

Researchers have documented a “honeymoon phase” following disasters, a period of intense social cohesion as people united by loss rally around each other — but it’s during the months and years that follow, that the weight of compounding trauma and loss sets in and recovery is most at risk. NA’s ongoing structure — weekly meetings, sponsorship, service commitments — gives people a framework that persists beyond the initial crisis response. grist

In eastern Kentucky, where devastating floods in 2022 destroyed nearly 9,000 homes in a region already ravaged by opioid abuse, recovery  participants described their peer support networks as the primary glue holding them together through months of displacement. “That’s a big thing in recovery,” relayed one Kentuckian in recovery from painkiller and methamphetamine addiction. “Asking for help.”

Narcotics Anonymous Meetings and Opioid Treatment

If you or someone you love has a narcotic addiction, the sooner support is in place, the better. Build your network before a crisis hits.

Search for Narcotics Anonymous meetings in any location in the country. Our directory has listings sorted by location or feel free to dial 800-934-1582(Sponsored) to speak with an expert.

A new study suggests that intermittent fasting could reduce the risk of opioid addiction, even when exposed to drugs. This potential breakthrough can affect millions of Americans caught in the grip of the opioid epidemic. 

Specifically, researchers at the University of Arizona found that fasting appeared to block the euphoric brain response that drives opioid addiction. The discovery complements local recovery groups like Narcotics Anonymous by opening a low-cost, accessible new avenue for treatment.

The Opioid Crisis Continues

The opioid epidemic continues to devastate communities across the United States. Fentanyl remains the leading driver of overdose deaths and has made opioid addiction more dangerous and harder to escape than at any previous point in the crisis. 

Against that backdrop, any research pointing toward new approaches to prevent or reduce opioid abuse carries significant weight.

That’s what makes this study noteworthy. It’s not a cure, but offers a potential complement to existing opioid treatment options.

What the Intermittent Fasting Study Found

Experts have long recognized that dietary changes are a key non-medication alternative to pain relief. Arizona, where the study originated, is also home to many holistic programs that take full advantage of the desert landscape. 

Doctoral student David Duron followed that train of thought and wondered if intermittent fasting could affect opioid treatment and addiction. Duron’s research team used mice as subjects, uncertain at the outset what they would find.

Their findings suggest that intermittent fasting could have a significant effect on opioid treatment. Fasting improved therapeutic benefits and limited negative side effects, particularly addiction, among mice.

Mice were placed on a six-hour daily eating window while receiving opioid injections over one week. At the study’s conclusion, the fasting group showed significantly improved and longer-lasting pain relief, including in a post-surgical pain model.

Even better, side effects didn’t increase among the mice in the fasting group. Corresponding author Dr. John Streicher noted this could have important implications for addiction specifically.

Fasting May Block the Opioid Reward Response

The mechanism goes to the heart of what makes opioid addiction so difficult to treat.

Opioids activate the brain’s reward circuit no matter the age, which is the basis of addiction. In control mice that ate freely, they reacted to morphine as expected. But in the intermittent fasting group, there was no evidence of reward. The mice didn’t appear to experience the euphoric effect of the drug, or at least didn’t associate the drug with euphoria. 

Fasting especially appeared to play a key role in drug tolerance. In the control group, opioid tolerance increased by as much as 100% over the study period. But the intermittent fasting group saw only a 40% increase in tolerance, meaning they required far smaller dose escalations.

Reduced tolerance escalation could translate to lower overdose risk in real-world opioid treatment settings.

Next Steps

The research team is now working to set up clinical trials based on these findings. The goal: testing intermittent fasting in patients undergoing opioid pain therapy. Dr. Streicher noted that unlike a new pharmaceutical, which can require a decade and millions of dollars to reach approval, a diet-based intervention can start almost immediately.

It is important to emphasize: this research is in early stages, conducted in mice, and should not be used as a substitute for evidence-based opioid addiction treatment. Narcotics Anonymous meetings, medication-assisted treatment (MAT) such as buprenorphine and methadone access remain proven interventions for those living with opioid addiction today.

Naloxone (brand name Narcan) is a life-saving medication that can reverse opioid overdoses and is available without a prescription in most states.

Opioid Addiction Treatment Now

If you or someone you love has an opioid addiction, evidence-based help is available right now. Narcotics Anonymous offers a strong first step with peer support and free and accessible community safe spaces. NA remains one of the most powerful elements of long-term recovery from narcotic addiction.

Dial 800-934-1582(Sponsored) to speak with an expert or browse our directory to find NA meetings anywhere in the country. Like recovery, fasting doesn’t take place in a vacuum, and having colleagues at your side strengthens fellowship for a brighter future.

New technology like artificial intelligence is giving public health officials a head start in fighting opioid addiction. This time, the response may come before an overdose ever happens.

For more than a decade, the standard playbook against the opioid epidemic has been largely reactive: distribute naloxone, respond to overdoses and treat survivors. Those efforts have saved countless lives. 

But a wave of artificial intelligence tools being deployed in California and across the country is shifting the paradigm toward prediction by identifying who’s at risk before they ever reach a crisis point. The Golden State boasts a wealth of resources from local Narcotics Anonymous meetings to pioneering artificial intelligence in the Silicon Valley. With AI spreading into every facet of daily life, those with substance use disorders can now enlist these digital tools to improve their health. 

AI Predicts Opioid Relapse Before It Happens

One promising development involves wearable technology and smartphones. Researchers backed by the National Institutes of Health analyzed data including mood, sleep, and stress logs to identify behavioral patterns that can lead to a return of drug use. They found that deep learning models could forecast high-risk relapse states with significant accuracy.

The science is in biology. When someone with opioid addiction enters a craving state, their heart rate variability and other biological signals lose their normal healthy complexity. AI can detect this drop in “physiological entropy” several days in advance. This allows time for a digital intervention like a supportive text or a call from a counselor before those at risk ever reach for a pill.

For people in recovery, that kind of early warning system represents a meaningful lifeline.

Fentanyl Detection Gets a New Weapon

The fentanyl crisis has always operated on a grim treadmill. Clandestine labs alter chemical structures of illicit fentanyl just enough to stay ahead of law enforcement and existing drug databases. Identifying a brand-new synthetic opioid has historically required matching it to a known sample. When no match exists, no one knows what they’re dealing with until people start dying.

Researchers at Lawrence Livermore National Laboratory tackled this problem by developing a “random forest” machine learning model that classifies chemicals based on their underlying molecular properties rather than their names. When a law enforcement officer or lab technician encounters a never-before-seen compound, they no longer have to wait for a database update to identify a lethal opioid.

In a fentanyl landscape where new analogues appear constantly, that capability could prevent mass overdose events before they unfold.

Wastewater Data Maps Opioid Abuse Hotspots in Real Time

Perhaps the most unexpected front in this fight runs beneath city streets. Through the CDC’s National Wastewater Surveillance System and California’s Cal-SuWers program, public health officials use wastewater-based epidemiology to track opioids at the community level.

When a person consumes fentanyl, their body metabolizes it into a compound called norfentanyl. Labs using liquid chromatography–mass spectrometry can detect these metabolic signatures in concentrations as small as parts per trillion. Machine learning algorithms then distinguish between drugs that were flushed versus drugs that were actually consumed. 

When this “digital sewage” data identifies a hotspot in a specific ZIP code, public health teams can deploy naloxone distribution, fentanyl test strips, and outreach workers directly to that community. They can meet folks where they are rather than waiting for emergency calls.

California Law Now Governs AI in Opioid Treatment

As these tools become embedded in clinical care, California is moving to regulate them. California Assembly Bill 489 prohibits AI systems from impersonating a medical professional or implying licensure where none exists. The law reinforces that no algorithm can serve as the sole decision-maker in a patient’s care so a human clinician must always remain in the loop.

The concern is real. Platforms like NarxCare already assign patients a risk score from 000 to 999 based on prescription history, pharmacy overlaps and doctor visits. But critics have raised “black box” concerns that a patient with a complex but legitimate pain history could be locked out of treatment by a rigid algorithm. 

For people seeking opioid treatment or managing chronic pain, these protections matter.

Opioid Addiction Recovery Right Now

Technology can identify patterns and predict risk, but it doesn’t replace human connection in recovery. For people navigating narcotic addiction today, the most proven pathways to long-term recovery still involve hands-on community effort, not just code.

• Medication-assisted treatment (MAT) remains the top treatment approach for opioid use disorders. MAT via buprenorphine and methadone is now more accessible than ever under California’s AB 1037 Substance Use Disorder Care Modernization Act, which removed abstinence-only barriers to care.

• Narcotics Anonymous (NA) continues to be a cornerstone of peer recovery for people with opioid addiction. NA meetings provide what no algorithm can: lived experience, accountability, and community. Meetings are available in nearly every city and county across the country, in person and online.

• Naloxone (Narcan) remains the single most important harm reduction tool available. It reverses opioid overdose within minutes and is available without a prescription at most pharmacies in California and across the United States.

If you or someone close has an opioid addiction, don’t delay. NA meetings go on all the time and across the country. Browse our directory or dial 800-934-1582(Sponsored) to speak with an expert today.

A peer-reviewed study is sending a critical warning through the opioid crisis community that the standard dose of naloxone (Narcan) may not be enough to reverse an overdose from newer synthetic opioids. For the millions of Americans affected by opioid addiction, not to mention the bystanders, families, and first responders trying to save lives, this research has life-or-death implications.

The Opioid Crisis Continues

The scale of the opioid epidemic in the United States remains staggering. Fentanyl and fentanyl-like drugs account for up to 79% of all opioid fatalities in the U.S. These aren’t abstract statistics. Behind each stat is a parent, child, or friend lost to a crisis driven largely by opioids.

Against this backdrop, naloxone has long been the front-line tool for reversing opioid overdoses. It’s distributed through harm reduction programs, pharmacies, and first responder kits nationwide. The new study, however, raises serious doubts about whether current naloxone protocols can adequately respond to the drugs now killing people.

What the New Research Found

The study found that a single dose of naloxone may not always reverse the respiratory depression caused by powerful synthetic opioids. Researchers tested naloxone in 30 folks, divided between those who had never used opioids and those who used them daily. 

The findings go further than just dose adequacy. Researchers noted that when someone receives naloxone, they may appear awake and alert before their breathing has actually returned to safe levels. In short, looking “awake” doesn’t mean they’re fully recovered.

This distinction has immediate implications for patient safety and dosing strategies and helps explain why re-sedation and delayed respiratory instability can still happen even after timely naloxone administration.

In other words: a person in the middle of a fentanyl overdose may seem to be responding to Narcan, but still stop breathing.

Fentanyl’s Role in Making Overdoses Harder to Reverse

Understanding why fentanyl overdoses are so hard to reverse requires understanding what fentanyl does in the body. Fentanyl can be up to 100 times stronger than morphine. It binds tightly to opioid receptors in the brain and central nervous system, suppressing the drive to breathe.

Because fentanyl binds tightly to opioid receptors, they’re often harder to reverse with just one dose of naloxone, especially for victims exposed to high levels or more potent drugs. Newer synthetic opioids like orphines are increasingly detected in the illicit drug supply and are even more potent than fentanyl.

Overdose Response Right Now

The study’s lead author, Dr. Maarten A. van Lemmen of Leiden University Medical Center, stated that the current doses of naloxone might not be enough to reverse overdoses caused by newer synthetic opioids. The researchers urge institutions to update overdose response guidelines accordingly.

To be clear: the study authors are not saying naloxone doesn’t work. Rather, they note that overdose victims often need more than one dose. They recommend the following:

• Call 911 immediately when an overdose is suspected, even if naloxone is administered. Naloxone can wear off, and additional doses are crucial to keep the person safe until responders arrive.

• Current overdose response guidelines were developed for older and weaker opioids. These guidelines have to be updated as opioids continue to become increasingly stronger. 

• For anyone carrying naloxone,  the practical guidance is: use multiple doses, don’t leave the person alone and always call 911.

Finding Help for Opioid Addiction

This research underscores that naloxone is a bridge, not a destination. Surviving an overdose is the first step, but long-term recovery from narcotic addiction requires ongoing treatment and support.

If you or someone you love is impacted by opioid addictions, help is always available right now.

For those just starting out or even rehab graduates who need reinforcement, Narcotics Anonymous holds free, peer-led meetings in thousands of communities across the country. 
NA is accessible, available and welcoming to all. Dial 800-934-1582(Sponsored) or browse our directory to find NA meetings in any location.

A new class of diabetes and weight-loss drugs is drawing attention from researchers, and the early data on opioid addiction may be the most compelling signal yet. GLP-1 receptor agonists, the drug class that includes semaglutide (sold as Ozempic and Wegovy), appear to reduce cravings, lower overdose risk and decrease substance use disorder diagnoses in real-world studies. But experts urge caution before the hype outpaces the evidence.

Introducing GLP-1 Drugs

GLP-1 receptor agonists were developed to treat type 2 diabetes and obesity by mimicking a hormone that regulates blood sugar and appetite. They’re typically administered once a week by injections. What researchers didn’t expect was that patients consistently reported reduced cravings—not just for food, but for alcohol, nicotine and opioids.

The leading theory is that GLP-1s modulate the brain’s reward pathways. These are the same neural circuits implicated in narcotic addictions. If confirmed, that mechanism would represent a genuinely novel approach to treating substance use disorders.

Opioid Addiction Data

The most striking evidence comes from a 2026 observational study of more than 600,000 U.S. veterans with type 2 diabetes. GLP-1 use correlated with lower risk of developing substance use disorders involving cannabis, cocaine and opioids. Among those with preexisting substance use disorders, GLP-1 takers had lower risks of hospitalization, overdose and suicidal ideation.

For those misusing opioids, the overdose finding is particularly significant. And the research is growing.

A separate randomized Phase 2 clinical trial focused on alcohol use disorder. It found that once-a-week semaglutide reduced drinking frequency and cravings over nine weeks compared to placebo. A recent systematic review also identified 33 registered clinical trials examining GLP-1s for substance use disorders, with growing interest in opioid and stimulant dependencies.

Fentanyl & the Stakes of New Treatment Options 

The urgency behind this research is major. The opioid epidemic is now dominated by illicitly manufactured fentanyl and death tolls continue to mount. Fentanyl is 50x more potent than heroin, and accidental overdoses are common even among experienced drug users. 

Current FDA-approved medications for opioid addiction are effective but fall victim to stigma, access barriers and treatment dropout. A non-opioid option like GLP-1 that reduces cravings can really expand the treatment toolkit, particularly for those who haven’t responded to existing therapies.

Some Gaps in the Science 

Addiction specialist Dr. Lynn Webster is careful to distinguish between “promising” and “proven.” For instance, the large veteran study is observational and doesn’t establish that GLP-1s directly caused the reductions in opioid cravings. Patients prescribed GLP-1s may differ from those who aren’t in ways that affect the results.

Researchers note that the consistency of effects across multiple substances and outcomes provides a strong rationale for dedicated clinical trials. But those trials haven’t yet been completed for opioid use disorder specifically.

Safety considerations also matter for people in addiction recovery. Common side effects like nausea, vomiting, diarrhea and appetite suppression can persuade folks to stop therapy altogether, and many GLP-1 benefits fade when treatment stops. 

In addiction care, insurance gaps and supply disruptions are common, which can lead participants to stop treatment if they can’t afford it. A 2026 analysis found that even brief interruptions in GLP-1 therapy were associated with elevated cardiovascular risk.

Seeking Help for Opioid Addiction Today 

GLP-1 drugs aren’t yet an approved or available treatment for opioid addiction. They’re still classified as diabetes and weight-loss medications, so doctors don’t prescribe them off-label for substance use disorders. The clinical trials needed to establish safety and efficacy in this population are still underway.

That means the most effective and evidence-based options for opioid addiction today remain prescriptions like buprenorphine or methadone, combined with counseling and peer support through programs like Narcotics Anonymous.

NA meetings provide community, accountability, and lived experience that no drug can replicate. For many people in recovery from opioid addiction, the combination of medication, therapy, and peer support through NA meetings make lasting recovery possible.

While GLP-1 remains in the testing stage, attending NA meetings can be a head start toward recovery. Call 800-934-1582(Sponsored) to speak with an expert or browse our directory to find meetings organized by location across the country.

For millions of Americans managing chronic pain, the choice has long felt impossible: live with debilitating pain or risk opioid addiction. A new compound identified by researchers offers a potential third option: DFNZ. But the road from the lab to the medicine cabinet is long, and people are suffering now.

The Impossible Choice for Chronic Pain Patients

The opioid crisis didn’t start in darkened back alleys. It began in doctor’s offices, where patients with legitimate, life-altering pain were prescribed medications that worked, so much so that they didn’t let go.

Let’s be clear. Most people don’t start out wanting to get addicted. Rather, those with chronic pain often can’t get out of bed, go to work, or parent their children. Doctors handed them prescriptions that offered relief and dependence in the same bottle.

Up to 12% of patients who’ve used opioids for chronic pain develop addictions. This statistic sounds manageable until you apply it to tens of millions of prescriptions. A large fraction of patients currently suffering from opioid use disorder and dying from opioid overdoses had their first exposure as pain patients.

This tragedy lies at the center of the opioid epidemic that DFNZ researchers are trying to solve.

About DFNZ and Opioid Addiction

Researchers at the National Institute on Drug Abuse (NIDA), led by Dr. Michael Michaelides, have identified a novel synthetic compound called N-desethyl-fluornitrazene—DFNZ for short—that relieved pain in rodents without causing tolerance or other indicators of potential addiction.

In animal studies, DFNZ produced robust relief for acute and inflammatory pain. The novel drug didn’t cause significant respiratory depression or meaningful withdrawal effects with repeated dosing. 

NIDA Director Dr. Nora D. Volkow reported that “developing a highly effective pain medication without these drawbacks would have enormous public health benefits.”

For chronic pain patients who have watched their prescription opioid dose climb over time, with tolerance building and withdrawal lurking, that statement carries enormous weight.

Chronic Pain Becomes Opioid Addiction

Chronic pain patients become so vulnerable to narcotic addiction because opioids interact with the brain over time. Research shows that opioid addiction primarily results from damage to the amygdala, leading to irregular reward-stress functions and heightened negative emotions during withdrawal that perpetuates the addiction cycle.

The cycle is cruel. Pain demands relief, opioids provide it, tolerance develops, higher doses are needed, and withdrawal becomes added suffering layered on top of the original pain. Many chronic pain patients describe not knowing where their pain ends and their opioid dependence begins.

Although alternatives to opioids exist to manage chronic pain, many people still fall back on prescriptions. Here’s where DFNZ, if it delivers on its early promise, can break this cycle at the molecular level.

DFNZ Differs From Fentanyl and Other Opioids

DFNZ activates the μ-opioid receptor, which is the same one targeted by morphine and fentanyl. The difference is that DFNZ doesn’t trigger the dopamine-driven reinforcement that leads to opioid addiction. This challenges the long-held assumption that strong μ-opioid activation inevitably causes dependence.

DFNZ belongs to a class of compounds roughly 1,000 times more potent than morphine, yet showing remarkably few adverse effects in preclinical models. For chronic pain sufferers who’ve built tolerance to regular opioids and require stronger doses for the same relief, the implications are significant.

Experts Urge Caution

History demands measured optimism. Oxycodone was once hailed as a safer, less addictive opioid. That promise contributed to the worst drug epidemic in American history.

Neuroscientists acknowledged DFNZ as a “promising approach,” but noted important limitations to address to avoid repeating the mistakes that led to the opioid crisis.

Significant additional research and regulatory scrutiny are required before any compound like DFNZ could reach the market. Human trials, FDA review, and years of post-market surveillance lie between today’s rodent data and a prescription pad. 

But for chronic pain patients with opioid addiction today, that timeline means more time  managing the pain and the drugs that have impacted their lives and those of loved ones.

Finding Help for Opioid Addiction While Managing Chronic Pain

Here’s where you can take steps today, rather than wait. If you’re living with chronic pain and opioid addiction, you’re not alone and you’re not to blame.

The first step often includes reaching out to your community for help and guidance. Going to grassroots, local groups for peer support works. Narcotics Anonymous offers anonymous, no-cost resources, sympathetic ears and shoulders, and assurance that you have help every step of the way. 

Getting started now is easier than it might seem. Call 800-934-1582(Sponsored) or browse our directory for comprehensive listings for group listings across the country.

For the first time in nearly a decade, opioid deaths are falling in Travis County, and public health officials say expanded access to naloxone (Narcan) is the primary reason. Drug-related deaths in the county dropped 22% from 2023 to 2024, and fatalities involving fentanyl fell by 36%. 

Travis County is home to a wide range of rehab services for drug addictions, from Narcotics Anonymous community meetings to modern inpatient hospitals. As with many counties in Texas, local and state officials have collaborated tirelessly to drive the death rate down, and these numbers show it. 

But advocates warn the progress is fragile, with federal funding cuts threatening to undo what took years to build.

The Opioid Crisis Hits Travis County

Travis County’s opioid crisis has been among the worst in the Lone Star State for years. The county’s seat and state capital, Austin, saw its peak of overdoses in mid-2023. And make no mistake, overdose deaths have remained the leading cause of accidental death in Travis County, ahead of both falls and motor vehicle accidents.

In January 2024, Austin-Travis County EMS averaged just over 100 opioid calls per month. By the next year, that number had dropped to about 50. A 50% drop occurred inside a single year.

Since 2022, Travis County has spent nearly $5 million on tackling the opioid overdose crisis and distributed more than 36,000 doses of Narcan to the community.

Driving the Decline in Opioid Deaths

Officials state clearly that opioid abuse hasn’t disappeared, but more people survive overdoses because the tools to reverse them are now within reach.

Officials noted this doesn’t necessarily mean fewer drugs are on the streets or that drug use itself is declining. Rather, mitigation methods reach more people.

EMS Division Chief Angela Carr said the availability of naloxone has been crucial, noting an increase of people administering Narcan prior to EMS arrival, which she called “instrumental” in affecting the death rate. 

Central Health, a nonprofit working with Travis County, is now expanding its fleet of naloxone distribution units, including to college campuses. The organization announced it will add 13 more Narcan distribution units to its existing 32, with all new sites ready by September. Officials plan to place four new units inside the Travis County Jail.

Fentanyl’s Role in the Austin Opioid Epidemic

Fentanyl has been the dominant driver of opioid deaths in Travis County throughout the crisis. The 2024 medical examiner’s report was a stark contrast to the prior year’s findings, which revealed the highest rate of accidental overdoses ever recorded in Travis County.

Fentanyl is a synthetic opioid 50-100x more potent than morphine. It contaminates the illicit drug supply broadly, including pills, heroin, and even stimulants like cocaine. This means people with any substance use disorder face fentanyl exposure risk. Naloxone (Narcan) is a medication approved by the FDA that rapidly reverses opioid overdoses and is available without a prescription in most states, including Texas.

Experts recommend that everyone learn to recognize overdose signs, such as small pupils, decreased responsiveness, and slow or absent breathing. Anyone who finds someone showing those signs should use naloxone immediately and call 911, since fatal opioids typically last longer than a single dose of intranasal naloxone.

Opioid Settlement Funding & the Federal Threat

Much of the progress in Travis County is financed by legal settlements with opioid manufacturers. Settlements from lawsuits against pharmaceutical companies have brought hundreds of thousands of dollars each year to fund Narcan doses and install the distribution units.

But that funding stream faces serious risk. Many nonprofits rely on COVID-19 era federal grants that might disappear after the Trump administration announced plans to cut $11.4 billion in addiction and mental health services. Texas Harm Reduction Alliance Executive Director Maggie Luna warned that without sustained investment, the progress made in lowering fatal drug overdoses could be at risk. 

Treatment Options and NA Meetings in Austin

Recovery from opioid addiction requires more than surviving an overdose. Travis County has invested in a range of treatment pathways alongside its harm reduction work. The county has launched public education campaigns and trained 1,000+ community members to recognize and respond to overdoses.

Austin-Travis County EMS has also emphasized a buprenorphine bridge program as a way of helping people by connecting those who survive an overdose with medication-assisted treatment before they leave EMS care.

For those seeking peer support, Narcotics Anonymous (NA) meetings remain a cornerstone of long-term recovery from opioid and narcotic addiction. NA meetings in the Austin and Travis County area are available daily, in-person and online, for anyone ready to take the next step.

Perhaps best of all, NA meetings are peer-led. You meet with others in your community who have the same experiences and backgrounds, and camaraderie forms for life-long support and fellowship. Our directory has a comprehensive list of NA meetings across the county, or feel free to call 800-934-1582(Sponsored) to speak to an expert.

The University of Idaho is working to close a critical gap in opioid addiction care that has already cost hundreds of lives in the state. A program is training Idaho clinicians on treating opioid use disorder. The goal is to equip frontline providers with the updated knowledge as fentanyl, xylazine, and other substances continue to reshape the opioid crisis across the state.

Idaho already has an impressive range of programs available to combat substance misuse. In the Gem State, local communities have banded together to start grassroots chapters of Narcotics Anonymous to offer peer support for those impacted by drug use.

Yet a significant share of people never receive proven treatment and a lack of trained providers is a major reason why. The need persists, with 264 Idahoans dying from opioid-related drug overdoses in 2023. 

The Opioid Crisis

The treatment gap is especially pronounced in rural states like Idaho, where access to opioid treatment programs (OTP) is limited by geography. While 20% with opioid use disorder achieve two years of abstinence without meds, those who relapse face a high risk of death. This makes medication-assisted treatment (MAT) a life-or-death issue for thousands of patients.

After someone has overdosed once, the chance of dying within the next year is one in ten.

The Opioid Care Gap in Idaho

According to Dr. Jacob Harris, an addiction medicine specialist at the VA Medical Center in Boise, one reason so few people receive medication is that Idaho’s health care community isn’t sufficiently trained to confidently treat the condition. Reticence is driven by lack of training, not knowing where to start and fear of doing it incorrectly. 

Under the University of Idaho’s School of Health and Medical Professions, Project ECHO Idaho operates the Opioids, Pain and Substance Use Disorders (OPSUD) series. Physicians, nurse practitioners and other primary care clinicians learn about the latest theories and practices for treating substance use disorders and pain.

The online series equips Idaho health care workers to prescribe meds and treat patients as laws, addiction trends and treatment recommendations change.

Fentanyl’s Role & the Shifting Drug Landscape

The opioid crisis hasn’t stood still. The opioid landscape has evolved over the past several years as people move from prescription opioids to street oxycodone, then heroin and now fentanyl. Illegal dealers often lace these opioids with other substances to intensify their effects.

Today, new drugs have emerged. Xylazine is a non-opioid veterinary tranquilizer that slows the heart rate and produces long-lasting euphoria and emerged in U.S. drug supplies in the early 2000s. Kratom is a non-federally regulated drug that mimics opioid-like sedative and euphoric effects and has impacted Idaho for more than a decade.

The 2025 OPSUD series consisted of learning how to ID, test and treat addiction or overdoses involving these substances.

One session highlighted a lesser-known fentanyl overdose symptom called “wooden chest syndrome,” in which rigid chest muscles make breathing extremely difficult. It’s a sobering reminder that even experienced clinicians have more to learn.

Medications and Expanding Access

The two primary medications for opioid use disorder are methadone, usually dispensed through opioid treatment programs, and buprenorphine, which patients can take at home. Since methadone is only available through OTP facilities typically located in larger cities, buprenorphine has expanded access to life-saving treatment in rural areas.

In addition, naloxone (brand name Narcan) is an emergency medication that can reverse an opioid overdose within minutes.

Prior to 2023, prescribers had to complete special DEA X-waiver training to prescribe medications for opioid use disorder. That requirement was removed. Now, with eight hours of continuing education per year, prescribers are licensed to provide controlled medications. The OPSUD series meets these requirements.

Harm Reduction & NA

Medication and clinical care comprise only part of the solution. Peer support and community-based recovery play a vital role in long-term opioid addiction recovery.

For many Idahoans, Narcotics Anonymous (NA) meetings provide free, peer-led support for people struggling with narcotic addiction at every stage of recovery. NA meetings are available in communities across Idaho in-person and online.

A landmark loan repayment initiative in Michigan is putting real money behind the push to close a devastating gap in opioid addiction treatment, and it could mean more help is finally coming to communities hardest hit by the opioid crisis.

Michigan’s Department of Health and Human Services (MDHHS) is offering student loan repayment to providers who begin or expand opioid addiction treatment programs, with awards ranging from $15,000 to $30,000.

The Opioid Crisis by the Numbers

The need driving this program is staggering. An estimated 1.3 million Michigan residents need treatment for substance use disorder but are not currently receiving it, according to the National Survey on Drug Use and Health. Workforce shortages are a central reason why.

Michigan currently ranks 40th in the nation in the number of substance use disorder counselors per adult with a disorder, a gap that leaves people with opioid addiction waiting for care that often never arrives. For many, that wait ends in overdose.

What Is Driving the Treatment Gap

The barriers keeping providers out of this field are well documented. High educational debt and the cost of addiction medicine certification deter many qualified clinicians from entering opioid treatment, particularly in rural and underserved areas.

Michigan’s loan repayment initiative is supported by the Michigan Opioid Healing and Recovery Fund, created using settlement funds from the nation’s three largest pharmaceutical distributors and opioid manufacturer Johnson and Johnson.

To date, the program has provided $3.7 million in loan repayment assistance to 202 providers and helped treat an additional 8,000 opioid use disorder clients.

Those are 8,000 people who got access to opioid addiction treatment they might not otherwise have received.

Who Is Eligible and How to Apply

Medical and osteopathic doctors, psychiatrists, nurse practitioners, physician assistants, case managers and substance use disorder counselors are eligible to apply if they are offering or expanding opioid treatment services.

Providers must serve at least two to three years at an approved substance use disorder treatment facility. For the current cycle, applications are being accepted through the MIOTA program portal at Michigan.gov/miota.

Fentanyl and the Ongoing Overdose Emergency

Programs like this exist because the opioid epidemic has not slowed. Fentanyl, a synthetic opioid up to 100 times more potent than morphine, now drives the overwhelming majority of overdose deaths in the United States.

It has infiltrated the street supply of heroin and counterfeit pills, making every use potentially fatal.

Expanding access to opioid addiction treatment, including medication-assisted treatment (MAT) with buprenorphine or methadone, is one of the most effective tools public health officials have to reduce overdose deaths.

Understanding Opioid Addiction and Treatment Options

Opioid addiction, also called opioid use disorder (OUD), is a chronic medical condition driven by changes in brain chemistry caused by repeated opioid exposure, whether from prescription painkillers, heroin or illicit fentanyl.

Effective opioid addiction treatment typically combines FDA-approved medications with behavioral health counseling.

Naloxone (Narcan) remains a critical life-saving intervention that can reverse an opioid overdose in minutes and is available without a prescription in most states.

Harm Reduction and Peer Recovery Through Narcotics Anonymous

Expanding the provider workforce addresses one side of the treatment gap. Peer recovery is the other. Narcotics Anonymous (NA) meetings offer free, community-based support for anyone struggling with narcotic addiction or opioid abuse, no referral or insurance required.

NA meetings operate on lived experience: people who have been through opioid addiction supporting others who are still fighting it.

For people not yet ready for formal treatment, or as a complement to medication-assisted therapy, NA meetings are a critical first step toward recovery.

Finding Help for Opioid Addiction

You can find Narcotics Anonymous meetings nationwide by searching Narcotics.com’s directory of NA meetings. Meetings are available in person and online, seven days a week. Call 800-934-1582(Sponsored) to speak with a treatment advisor today.